1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

  • June 2013
  • 129 pages
  • La Merie Publishing
Report ID: 1497384

Summary

Table of Contents

Search Inside

A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed. The detailed target pipeline assessments put emphasis on the competitive situation regarding stage of development, inhibitor profile, half-life, administration frequency, clinical success and especially time to approval/market. The pipelines of the clinically active companies are described and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, papers), corporate information (press releases, presentations, reports, SEC filings). All information is referenced.

Combined product sales of the three classes olf recombinant coagulation factors used in hemophilia were US$ 7.172 mln in 2012. The pipeline of new recombinant coagulation factors is maturing and the first molecules are under regulatory review by the FDA and the EMA and many have entered pivotal clinical studies. There are 46 different molecules and R&D approaches for novel recombinant coagulation factors for hemophilia A and B in the pipeline of which 24 are in clinical development of under regulatory review. Given this tight competition, time-to-market will be an important success. This report will explain the potential development and approval timelines of each of the advanced molecules.

What will you find in this report?

• Historical sales data of the recombinant coagulation factors VIII, IX, VIIa and II;
• Historical growth rates and a 5-year sales forecast of each class of recombinant factors;
• Reasons for failure and profiles of failed recombinant coagulation factors;
• Detailed profiles of clinical stage recombinant coagulation factors;
• Technologies used for creation of novel recombinant coagulation factors;
• Preclinical stage recombinant coagulation factors;
• New approaches: alternative procoagulants / adjuncts and gene therapy;
• Pipeline analysis and assessment for each recombinant coagulation factor class;
• Comparative data on clinical inhibitor formation and discussion of its relevance;
• Comparison of half-life prolongation and its impact on administration frequency;
• Comparison of the time to approval for each clinical stage recombinant coagulation factor;
• Company pipeline and competitive position of each major player in the field

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Factor VIII Deficiency Treatment Market 2017-2021

  • $ 3500
  • Industry report
  • March 2017
  • by Infiniti Research Limited

About Factor VIII Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia ...

Factor VIII Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Factor VIII Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Factor VIII worldwide and by countries in North America, Europe, Japan, BRIC, ...

Factor VIII / Von Willebrand factor Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Factor VIII / Von Willebrand factor Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Factor VIII / Von Willebrand factor worldwide and ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.